Research advances of m6A methylation modification in digestive system neoplasms

doi:10.3760/cma.j.cn371439-20210906-00136

Abstract

Abstract:

N⁶-methyladenosine (m⁶A) methylation modification is defined as the methylation at the N⁶ position of adenosine. This dynamic process is regulated by writer, eraser and reader. Accumulating evidence indicates that m⁶A methylation modification is involved in the initiation and development of various digestive system neoplasms including proliferation, invasion, metastasis and chemoresistance. A further understanding about the role of m⁶A methylation modification in digestive system neoplasms will benefit the development of a novel precise diagnostic and therapeutic strategy and finally improve the overall prognosis of patients.

Key words: Methylation, Digestive system neoplasms, Biomarker, N⁶-methyladenosine

Liu Peipei, Yang Mengxue, Yan Xuebing. Research advances of m⁶A methylation modification in digestive system neoplasms[J]. Journal of International Oncology, 2021, 48(11): 688-692.

References 42

[1]	Darwiche N. Epigenetic mechanisms and the hallmarks of cancer: an intimate affair[J]. Am J Cancer Res, 2020, 10(7):1954-1978. pmid: 32774995
[2]	Chen M, Wong CM. The emerging roles of N⁶-methyladenosine (m⁶A) deregulation in liver carcinogenesis[J]. Mol Cancer, 2020, 19(1):44. DOI: 10.1186/s12943-020-01172-y. doi: 10.1186/s12943-020-01172-y
[3]	Wang Q, Chen C, Ding Q, et al. METTL3-mediated m⁶A modification of HDGF mRNA promotes gastric cancer progression and has prognostic significance[J]. Gut, 2020, 69(7):1193-1205. DOI: 10.1136/gutjnl-2019-319639. doi: 10.1136/gutjnl-2019-319639
[4]	Tian J, Zhu Y, Rao M, et al. N⁶-methyladenosine mRNA methy-lation of PIK3CB regulates AKT signalling to promote PTEN-deficient pancreatic cancer progression[J]. Gut, 2020, 69(12):2180-2192. DOI: 10.1136/gutjnl-2019-320179. doi: 10.1136/gutjnl-2019-320179
[5]	Song P, Feng L, Li J, et al. β-catenin represses miR455-3p to stimulate m⁶A modification of HSF1 mRNA and promote its translation in colorectal cancer[J]. Mol Cancer, 2020, 19(1):129. DOI: 10.1186/s12943-020-01244-z. doi: 10.1186/s12943-020-01244-z
[6]	Wang T, Kong S, Tao M, et al. The potential role of RNA N⁶-methyladenosine in cancer progression[J]. Mol Cancer, 2020, 19(1):88. DOI: 10.1186/s12943-020-01204-7. doi: 10.1186/s12943-020-01204-7
[7]	Wang X, Lu Z, Gomez A, et al. N⁶-methyladenosine-dependent regulation of messenger RNA stability[J]. Nature, 2014, 505(7481):117-120. DOI: 10.1038/nature12730. doi: 10.1038/nature12730
[8]	Zhu ZM, Huo FC, Pei DS. Function and evolution of RNA N⁶-methyladenosine modification[J]. Int J Biol Sci, 2020, 16(11):1929-1940. DOI: 10.7150/ijbs.45231. doi: 10.7150/ijbs.45231
[9]	Ji P, Wang X, Xie N, et al. N⁶-methyladenosine in RNA and DNA: an epitranscriptomic and epigenetic player implicated in determination of stem cell fate[J]. Stem Cells Int, 2018, 2018:3256524. DOI: 10.1155/2018/3256524.
[10]	Lu J, Qian J, Yin S, et al. Mechanisms of RNA N⁶-methyladenosine in hepatocellular carcinoma: from the perspectives of etiology[J]. Front Oncol, 2020, 10:1105. DOI: 10.3389/fonc.2020.01105. doi: 10.3389/fonc.2020.01105
[11]	Imam H, Khan M, Gokhale NS, et al. N⁶-methyladenosine modification of hepatitis B virus RNA differentially regulates the viral life cycle[J]. Proc Natl Acad Sci U S A, 2018, 115(35):8829-8834. DOI: 10.1073/pnas.1808319115. doi: 10.1073/pnas.1808319115
[12]	Fang Q, Chen H. The significance of m⁶A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma[J]. Mol Med, 2020, 26(1):60. DOI: 10.1186/s10020-020-00185-z. doi: 10.1186/s10020-020-00185-z
[13]	Chen M, Wei L, Law CT, et al. RNA N⁶-methyladenosine methyltransferase-like 3 promotes liver cancer progression through YTHDF2-dependent posttranscriptional silencing of SOCS2[J]. Hepato-logy, 2018, 67(6):2254-2270. DOI: 10.1002/hep.29683.
[14]	Zhang C, Huang S, Zhuang H, et al. YTHDF2 promotes the liver cancer stem cell phenotype and cancer metastasis by regulating OCT4 expression via m⁶A RNA methylation[J]. Oncogene, 2020, 39(23):4507-4518. DOI: 10.1038/s41388-020-1303-7. doi: 10.1038/s41388-020-1303-7
[15]	Cheng X, Li M, Rao X, et al. KIAA1429 regulates the migration and invasion of hepatocellular carcinoma by altering m⁶A modification of ID2 mRNA[J]. Onco Targets Ther, 2019, 12:3421-3428. DOI: 10.2147/ott.s180954. doi: 10.2147/OTT
[16]	Chen Y, Peng C, Chen J, et al. WTAP facilitates progression of hepatocellular carcinoma via m⁶A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019, 18(1):127. DOI: 10.1186/s12943-019-1053-8. doi: 10.1186/s12943-019-1053-8
[17]	Zuo X, Chen Z, Gao W, et al. M⁶A-mediated upregulation of LINC00958 increases lipogenesis and acts as a nanotherapeutic target in hepatocellular carcinoma[J]. Hematol Oncol, 2020, 13(1):5. DOI: 10.1186/s13045-019-0839-x.
[18]	Zhao M, Jia M, Xiang Y, et al. METTL3 promotes the progression of hepatocellular carcinoma through m⁶A-mediated up-regulation of microRNA-873-5p[J]. Am J Physiol Gastrointest Liver Physiol, 2020, 319(5):G636. DOI: 10.1152/ajpgi.00161.2020. doi: 10.1152/ajpgi.00161.2020
[19]	Lin Y, Wei X, Jian Z, et al. METTL3 expression is associated with glycolysis metabolism and sensitivity to glycolytic stress in hepatocellular carcinoma[J]. Cancer Med, 2020, 9(8):2859-2867. DOI: 10.1002/cam4.2918. doi: 10.1002/cam4.v9.8
[20]	Zhou Y, Yin Z, Hou B, et al. Expression profiles and prognostic significance of RNA N⁶-methyladenosine-related genes in patients with hepatocellular carcinoma: evidence from independent datasets[J]. Cancer Manag Res, 2019, 11:3921-3931. DOI: 10.2147/CMAR.S191565. doi: 10.2147/CMAR.S191565 pmid: 31118805
[21]	Wu X, Zhang X, Tao L, et al. Prognostic value of an m⁶A RNA methylation regulator-based signature in patients with hepatocellular carcinoma[J]. Biomed Res Int, 2020, 2020: 2053902. DOI: 10.1155/2020/2053902.
[22]	Zhang J, Bai R, Li M, et al. Excessive miR-25-3p maturation via N⁶-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression[J]. Nat Commun, 2019, 10(1):1858. DOI: 10.1038/s41467-019-09712-x. doi: 10.1038/s41467-019-09712-x
[23]	Wang M, Liu J, Zhao Y, et al. Upregulation of METTL14 mediates the elevation of PERP mRNA N⁶ adenosine methylation promoting the growth and metastasis of pancreatic cancer[J]. Mol Cancer, 2020, 19(1):130. DOI: 10.1186/s12943-020-01249-8. doi: 10.1186/s12943-020-01249-8 pmid: 32843065
[24]	Guo X, Li K, Jiang W, et al. RNA demethylase ALKBH5 prevents pancreatic cancer progression by posttranscriptional activation of PER1 in an m⁶A-YTHDF2-dependent manner[J]. Mol Cancer, 2020, 19(1):91. DOI: 10.1186/s12943-020-01158-w. doi: 10.1186/s12943-020-01158-w
[25]	Hou J, Wang Z, Li H, et al. Gene signature and identification of clinical trait-related m⁶A regulators in pancreatic cancer[J]. Front Genet, 2020, 11:522. DOI: 10.3389/fgene.2020.00522. doi: 10.3389/fgene.2020.00522
[26]	Geng Y, Guan R, Hong W, et al. Identification of m⁶A-related genes and m⁶A RNA methylation regulators in pancreatic cancer and their association with survival[J]. Ann Transl Med, 2020, 8(6):387. DOI: 10.21037/atm.2020.03.98. doi: 10.21037/atm.2020.03.98 pmid: 32355831
[27]	Taketo K, Konno M, Asai A, et al. The epitranscriptome m⁶A writer METTL3 promotes chemo- and radioresistance in pancreatic cancer cells[J]. Int J Oncol, 2018, 52(2):621-629. DOI: 10.3892/ijo.2017.4219.
[28]	Wang Q, Geng W, Guo H, et al. Emerging role of RNA methyltransferase METTL3 in gastrointestinal cancer[J]. Hematol Oncol, 2020, 13(1):57. DOI: 10.1186/s13045-020-00895-1.
[29]	Yang DD, Chen ZH, Yu K, et al. METTL3 promotes the progression of gastric cancer via targeting the MYC pathway[J]. Front Oncol, 2020, 10:115. DOI: 10.3389/fonc.2020.00115. doi: 10.3389/fonc.2020.00115
[30]	Yan J, Huang X, Zhang X, et al. LncRNA LINC00470 promotes the degradation of PTEN mRNA to facilitate malignant behavior in gastric cancer cells[J]. Biochem Biophys Res Commun, 2020, 521(4):887-893. DOI: 10.1016/j.bbrc.2019.11.016. doi: 10.1016/j.bbrc.2019.11.016
[31]	Yue B, Song C, Yang L, et al. METTL3-mediated N⁶-methyladenosine modification is critical for epithelial-mesenchymal transition and metastasis of gastric cancer[J]. Mol Cancer, 2019, 18(1):142. DOI: 10.1186/s12943-019-1065-4. doi: 10.1186/s12943-019-1065-4
[32]	Xie JW, Huang XB, Chen QY, et al. m⁶A modification-mediated BATF2 acts as a tumor suppressor in gastric cancer through inhibition of ERK signaling[J]. Mol Cancer, 2020, 19(1):114. DOI: 10.1186/s12943-020-01223-4. doi: 10.1186/s12943-020-01223-4
[33]	Pi J, Wang W, Ji M, et al. YTHDF1 promotes gastric carcinogenesis by controlling translation of FZD7[J]. Cancer Res, 2020, 11: canres.0066.2020. DOI: 10.1158/0008-5472.can-20-0066. DOI: 10.1158/0008-5472.can-20-0066.
[34]	Li Y, Zheng D, Wang F, et al. Expression of demethylase genes, FTO and ALKBH1, is associated with prognosis of gastric cancer[J]. Dig Dis Sci, 2019, 64(6):1503-1513. DOI: 10.1007/s10620-018-5452-2. doi: 10.1007/s10620-018-5452-2
[35]	Shen C, Xuan B, Yan T, et al. m⁶A-dependent glycolysis enhances colorectal cancer progression[J]. Mol Cancer, 2020, 19(1):72. DOI: 10.1186/s12943-020-01190-w. doi: 10.1186/s12943-020-01190-w
[36]	Xiang S, Liang X, Yin S, et al. N⁶-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression[J]. Am J Transl Res, 2020, 12(5):1789-1806. pmid: 32509177
[37]	Peng W, Li J, Chen R, et al. Upregulated METTL3 promotes metastasis of colorectal cancer via miR-1246/SPRED2/MAPK signaling pathway[J]. Exp Clin Cancer Res, 2019, 38(1):393. DOI: 10.1186/s13046-019-1408-4.
[38]	Uddin MB, Roy KR, Hosain SB, et al. An N⁶-methyladenosine at the transited codon 273 of p53 pre-mRNA promotes the expression of R273H mutant protein and drug resistance of cancer cells[J]. Biochem Pharmacol, 2019, 160:134-145. DOI: 10.1016/j.bcp.2018.12.014. doi: 10.1016/j.bcp.2018.12.014
[39]	Li T, Hu P S, Zuo Z, et al. METTL3 facilitates tumor progression via an m⁶A-IGF2BP2-dependent mechanism in colorectal carcinoma[J]. Mol Cancer, 2019, 18(1):112. DOI: 10.1186/s12943-019-1038-7. doi: 10.1186/s12943-019-1038-7
[40]	Yang X, Zhang S, He C, et al. METTL14 suppresses proliferation and metastasis of colorectal cancer by down-regulating oncogenic long non-coding RNA XIST[J]. Mol Cancer, 2020, 19(1):46. DOI: 10.1186/s12943-020-1146-4. doi: 10.1186/s12943-020-1146-4
[41]	Ji L, Chen S, Gu L, et al. Exploration of potential roles of m⁶A regulators in colorectal cancer prognosis[J]. Front Oncol, 2020, 10:768. DOI: 10.3389/fonc.2020.00768. doi: 10.3389/fonc.2020.00768
[42]	Meng Y, Li S, Gu D, et al. Genetic variants in m⁶A modification genes are associated with colorectal cancer risk[J]. Carcinogenesis, 2020, 41(1):8-17. DOI: 10.1093/carcin/bgz165.

Research advances of m⁶A methylation modification in digestive system neoplasms

RichHTML

PDF

Knowledge

Abstract

Cite this article

share this article

References 42

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Xie Shuping, Sun Yahong, Wang Chao. Prediction of efficacy of early-stage tumor markers combined with NLR and PLR for immunotherapy in gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 157-165.
[2]	Liu Yulan, Jing Haiyan, Sun Jing, Song Wei, Sha Dan. Advances in predicting efficacy and prognostic markers of immunotherapy for gastric cancer [J]. Journal of International Oncology, 2024, 51(3): 175-180.
[3]	Li Lixi, Zhang Di, Luo Yang, Ma Fei. Clinical application of PARP inhibitors in breast cancer [J]. Journal of International Oncology, 2023, 50(2): 91-96.
[4]	Jiang Shan, Xu Yangtao, Liu Xin, Chen Wenliang, Xu Ximing. Predictive value of baseline peripheral blood inflammatory biomarkers for prognosis in patients with advanced hepatocellular carcinoma treated with immunotherapy combined with targeted therapy [J]. Journal of International Oncology, 2023, 50(10): 600-607.
[5]	He Zhefeng, Wu Yiyang, Li Zhenjun, Ying Xiaojiang. Predictive value of inflammatory markers in colorectal cancer [J]. Journal of International Oncology, 2022, 49(9): 560-563.
[6]	Hu Ru, Li Donglin, Yan Xuebing. Methyltransferase like protein 14 and tumor [J]. Journal of International Oncology, 2022, 49(8): 478-483.
[7]	Liu Xiaoting, Liu Yang, Zhang Huanqin, Xing Jinliang, Quan Zhibo. Application of tumor biomarkers in the diagnosis and prognosis of hepatocellular carcinoma [J]. Journal of International Oncology, 2022, 49(6): 371-375.
[8]	Lei Yan, Zhang Gehong. Predictive value of biomarkers in immunotherapy of advanced non-small cell lung cancer [J]. Journal of International Oncology, 2022, 49(12): 739-744.
[9]	Xu Kai, Wen Gang, Li Rui, Tian Yuan. Research progress on the prognostic value of the ratio of lymphocytes to C-reactive protein in digestive system neoplasms [J]. Journal of International Oncology, 2022, 49(10): 627-629.
[10]	Hu Guangyue, Yin Hong, Zhang Hui, Luo Hong. Efficacy predictors of immune checkpoint inhibitors in the treatment of metastatic gastric cancer [J]. Journal of International Oncology, 2021, 48(8): 498-501.
[11]	Zhuang Weitao, Qiao Guibin. Research and application of liquid biopsy based on epigenetic markers in the diagnosis and treatment of solid tumors [J]. Journal of International Oncology, 2021, 48(6): 358-361.
[12]	Ju Xinyue, Hu Chunmei, Zhao Yue, Tang Yan. CDX2 and gastrointestinal neoplasms [J]. Journal of International Oncology, 2021, 48(6): 374-376.
[13]	Wang Hui, Xia Rong, Wei Qingwen, Wan Yixin. Risk factors and predictive biomarkers of immune checkpoint inhibitor-associated pneumonia in non-small cell lung cancer [J]. Journal of International Oncology, 2021, 48(5): 296-301.
[14]	Li Suyao, Huang Junxing. Research progress of biomarkers for predicting the efficacy of immunotherapy for tumor [J]. Journal of International Oncology, 2021, 48(4): 220-224.
[15]	Wu Hansheng, Huang Shujie, Zhuang Weitao, Ding Yu, Gao Zhen, Qiao Guibin. m⁶A methylation modification and lung cancer [J]. Journal of International Oncology, 2021, 48(4): 225-230.